Currently, reduction of sexual drive in patients with psychiatric disorders can be achieved with antihormonal pharmacotherapy (medroxyprogesterone acetate, antiandrogen cyproterone acet ate, GnRH agonists), selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioural therapy. 1 Although solid evi dence is lacking for antihormonal treatment, 2 some countries de cide by verdict to treat sex offenders with antihormonal therapy in order to reduce the risk for reoffending. 3 Large metaanalyses have suggested that antihormonal therapy reduces recidivism rates in sexual offenders. 4, 5 Therefore the World Federation of Societies of Biological Psychiatry has suggested guidelines for the biological treatment of paraphilias, including antihormonal and SSRI treatment. 6 In addition to sexual offenders, paraphilic and hypersexual patients who have never shown delinquent behaviour and ex perience severe distress from recurrent sexual urges demand antihormonal therapy. 7 The sexual urges of these patients are linked to qualitative (e.g., pedophilic sexual interest) and/or quantitative (hypersexual, compulsive or addictive) abnormal ities, and they seek medical assistance in hopes of overcoming or at least controlling sexual urges that could bring them into conflict with society and the law or that impair their social and occupational functioning. Treatment of these patients and of sex offenders, however, raises thorny ethical problems because potential harm to a third person (e.g., in sexual sadism or pe dophilic disorder) has to be considered. The meager evidence for these treatments further complicates ethical concerns; a first doubleblind controlled clinical trial for antihormonal treat ment is only in the planning stages. 8 Moreover, patients have to accept severe side effects like osteoporosis, mood disturb ances and increased risk for thromboembolic complication as well as cerebrovascular and cardiovascular diseases that can be associated with antihormonal treatment. 9 Thibaut and col leagues 6 therefore suggested ethical standards for the indica tion of antihormonal therapy.
A targeted therapy that reduces sexual drive specifically without the systemic hormonal disturbances of antiandro gens would be desirable. While it seems unlikely that bio logic al therapy would target the appearance of distinct para philic thoughts in the brain, neural circuits that generate sexual drive could be identified and inhibition of these cir cuits might lead to a reduction of sexual urge and hence re lieve patients and open new venues for psychotherapy.
With the advent of deep brain stimulation (DBS) to treat a number of psychiatric disorders (targeting, for example, de pressive or compulsive symptoms) we also suggest sexual drive as a potential target for DBS. Brain areas that are associ ated with sexual arousal have been repeatedly identified, and these may be discussed as targets for DBS (for a review see Mohnke and colleagues 10 and for a recent metaanalysis see Kühn and Gallinat 11 ). However, based on experiences with earlier stereotaxic brain lesions, the best evidence exists for the inhibition of the ventromedial hypothalamus.
From 1962 to the late 1970s a considerable number of people in Germany received stereotaxic brain lesions to treat para philic sexual desires (e.g., pedophilic disorder and exhibition ism). Most prominent was the unilateral lesion of the ventro medial hypothalamus. Results were published in case series To date there are few treatment options to reduce high sexual drive or sexual urges in paraphilic patients with a risk for sexual offending. Pharmacological therapy aims to reduce sexual drive by lowering testosterone at the cost of severe side effects. We hypothesize that high sexual drive could also be reduced with deep brain stimulation (DBS) of circuits that generate sexual drive. This approach would help to avoid systemic side effects of antiandrogenic drug therapies. So far the best investigated target to reduce sexual drive is the ventromedial hypothalamus, which was lesioned unilaterally and bilaterally by stereotaxic interventions in paraphilic patients in the 1970s. Here, we discuss DBS as a treatment strategy in patients with severe paraphilic disorders with a serious risk of sexual offending. There are profound ethical and practical issues associated with DBS treatment of paraphilic patients that must be solved before considering such a treatment approach.
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and promised remarkable effects that induced a reduction of sexual drive with fewer side effects than pharmacological treatment with antiandrogens. 12 Roeder and colleagues 12 con ducted a case series of 10 patients; 9 received unilateral stereo taxic ablation of the ventromedial hypothalamic nucleus (Cajal) and 1 received bilateral lesions. From today's perspec tive, however, only half of these patients would have been considered to have a paraphilic disorder (n = 4 patients with pedophilic disorder). The others were homosexual, which in those days was considered to be a psychiatric diagnosis; homo sexuality was deleted from the Diagnostic and Statistical Manual of Mental Disorders in 1973. Irrespective of the diagno sis, it was reported that stereotaxic lesion of the ventromedial hypothalamus reduced sexual drive remarkably.
12,13 Subse quently, 75 people (74 men, 1 woman) were documented to have been treated with ventromedial hypothalamotomy in Germany. 13 However, Bernd Lichtenberg, who had been oper ated in Hamburg in 1976, killed a 10yearold boy 3 years later.
14 Subsequently, psychosurgery of sex offenders became a major political topic in Germany and was profoundly criti cized 13, 15 and finally abandoned. Unfortunately, a systematic followup examination of the operated individuals was never published in a scientific peerreviewed journal. Schmidt and Schorsch 13 reported that initial endocrinological disturbances after the operation normalized after 6-10 months but that weight gain lasted in most patients. Hebestreit 16 completed a dissertation in 1989 about psychological examinations before and after hypothalamotomy and reported that patients oper ated in Hamburg exhibited no neurocognitive deficits after surgery. Timmann and Müller 17 selfpublished a book in 2003 after interviewing 26 of the operated individuals many years after surgery and reported that longterm followup and satis faction of these individuals was surprisingly good. These 2 publications 16, 17 never underwent a formal peer review, how ever, and cannot be interpreted as evidencebased.
In contrast to other psychosurgical interventions in which brain lesions had volumes up to 15 cm 3 , the ventromedial hypo thalamotomy lesioned an area of only 80 mm 3 . As a phyl logenetically old brain structure, the ventromedial hypothala mus is present in mice and men. Two major publications have recently highlighted the role of the murine ventromedial hypo thalamus in male aggression and sexual behaviour. 18, 19 Lin and colleagues 18 demonstrated that acute optogenetic stimulation of neurons in the ventrolateral subdivision of the ventromedial hypothalamus induced aggression in male mice. Stimulation led to attacks toward an intruder. The fighting ceased when the stimulation stopped. The authors also identified cells in the same brain region that were active during mating and that were distinct from the neurons that were active during fighting. Yang and colleagues 19 genetically ablated neurons that carried a progesterone receptor (roughly 50%) within the same ventro lateral division of the ventromedial hypothalamus of male mice. Chronic ablation of these neurons significantly reduced mating behaviour and aggression. Interestingly, sex discrimina tion, emotional behaviours and territory marking were not af fected. These recent studies indicate that acute activation of neurons in the ventromedial hypothalamus induces aggression in male mice and chronic inhibition reduces aggression and mating behaviour, confirming the assumption that the ventro medial hypothalamus is involved in the generation of sexual behaviour and that its function may correlate with sexual drive. A recent metaanalysis of human brain response to sexual stimu li found an activation of the hypothalamus.
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With the advent of DBS to treat a number of psychiatric dis orders, sexual drive may be discussed as a possible therapeutic target for DBS. Compared with psychosurgical procedures, DBS is less destructive but rather reversible and more adjust able to the clinical symptoms and side effects. Small case series of DBS in the posterior hypothalamus to reduce aggressive be haviour have been performed successfully. 20, 21 However, DBS in paraphilic patients will exceedingly touch sensitive practical and even more ethical issues. Especially with regard to experi ences in Germany with psychosurgical intervention in patients with deviant sexual behaviour without sufficient proof of effi cacy and the history of involuntary castration of sex offend ers, 22 it is extremely important that future studies should com ply with rigorous scientific assessment and great ethical caution. The indication for DBS has to accrue from severe psycho logical strain, but on the other hand, appropriate can didates have to be capable of understanding risks and giving informed consent without any form of legal pressure. Manda tory DBS (as well as mandatory antiandrogen medication) should absolutely not be an option (for an ethical discussion of mandatory v. voluntary treatment of sexual offenders see Harrison   3 ). Preferably, patients with paraphilic disorders (sex ual sadism and pedophilia) who have uncontrollable sexual urges and a concomitant high risk for sexual offense 6 could eventually be eligible candidates. The treatment of these candi dates should be openly debated to weigh ethical issues on an individual basis, as for example in the case of a sexual offender who demanded surgical castration after it had been aban doned in Europe. 23 The motivation for DBS treatment should not be connected to any hopes/promises of prematurely leav ing prison or a forensic treatment facility as in the 1970s when most of the imprisoned sexual offenders were released after the operation. The boundary between treatment and punish ment must be very clear. Thus, we propose that only those in dividuals who desire DBS treatment because they suffer from their sexuality to a high degree, have a high risk of severe sex ual offending or in whom antiandrogens have been ineffective or have caused unacceptable side effects should be eligible for DBS. In any case, prosecuted sexual offenders could be eligible for DBS treatment only after it has been clearly demonstrated that DBS is superior to other treatments under certain condi tions. But even with such a scientific proof of efficacy we would still face the problem that detained convicts may have a reduced capacity to give informed consent. 24 A rigorous risk-benefit assessment would have to demon strate that individual distress and risk surmounts the risk for side effects (e.g., intracerebral bleeding). Yet, even if suitable patients have been identified, a plethora of ethical and judi cial questions would have to be considered: Is legal responsi bility affected by DBS? Who is responsible if such a patient commits a sexual offense because the stimulator is not work ing properly? Who is allowed to reduce or stop the stimula tion? What followup care is mandatory?
With our suggestions and concerns, we hope to stimulate a discussion to scrutinize these questions in more detail before anyone in the scientific community starts treating paraphilic patients with DBS. Stimulation might have fewer side effects than pharmacological therapies, as has been repeatedly dem onstrated in patients with Parkinson disease. 25 However, con sequences of a selective inhibition of sexual thoughts and urges are difficult to anticipate. Unexpected and undesirable personality changes have been reported following DBS in clinical practice. 26 These changes might unintentionally im pede the individual's ability to gain control over paraphilic urges or even impair behavioural control.
Unlike in 1962 when paraphilic patients were treated without a prior scientific debate, now we must discuss eth ical concerns and possible side effects before DBS treatment can be considered.
